Skip to content

A Tailored Screening and Smoking Cessation Program for the LGBTQ Community of Seattle

Tailoring Screening and Smoking Cessation for the LGBTQ Community

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05304390
Enrollment
53
Registered
2022-03-31
Start date
2022-06-06
Completion date
2024-10-28
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Carcinoma

Brief summary

This clinical trial develops a tailored screening and smoking cessation program for the lesbian, gay, bisexual, transgender (trans) and queer (LGBTQ) community of Seattle, Washington. A lung cancer screening program may help LGTBQ people who smoke overcome unique barriers that keep them from receiving preventive care, and constantly facing healthcare discrimination. Members of the LGBTQ community have historically smoked at higher rates than the general population and thus could benefit greatly from targeted efforts to improve lung cancer screening and smoking cessation implementation.

Detailed description

OUTLINE: AIM 1: Stakeholders (community organization leaders, medical providers of LGBTQ patients, and LGBTQ community members and tobacco users) participate in an interview over 45 minutes to 1 hour. AIM 2: Participants participate in focus groups over 1-1.5 hours. AIM 3: Participants receive a patient navigation intervention consisting of a series of points of contact (mostly via telephone) between the patient navigator/tobacco treatment specialist (PN/TTS) and includes: 1) An introduction and enrollment in LCS, 2) facilitation of a shared decision-making (SDM) visit with the LCS-dedicated nurse practitioner, 3) individual assessment of barriers and facilitators to in-person low-dose CT screening, 4) explanation of results and needed follow-up, and 5) follow-up reminders. Participants also undergo carbon monoxide measurement by exhaling into a disposable monitor for 10 seconds at the initial visit and the post-intervention visit. The PN may also provide an intervention for smoking cessation. After completion of Aim 3 study intervention, participants are followed up at 3 months.

Interventions

BEHAVIORALPatient Navigation

Receive patient navigation intervention

OTHERQuestionnaire Administration

Ancillary studies

BEHAVIORALSmoking Cessation Intervention

Receive an intervention for smoking cessation

Undergo carbon monoxide measurement

Sponsors

LUNGevity Foundation
CollaboratorOTHER
Fred Hutchinson Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* AIM 1 MEDICAL PROVIDER OF LGBTQ PATIENTS: Age minimum of 18 * AIM 1 MEDICAL PROVIDER OF LGBTQ PATIENTS: Affiliation with Cancer Consortium, Seattle's LGBTQ Center, or other organization serving LGBTQ persons * AIM 1 MEDICAL PROVIDER OF LGBTQ PATIENTS: Identifies as providing primary care or specialty care to largely LGBTQ population (doctor of medicine \[MD\], registered nurse \[RN\], physician assistants \[PA\], advanced registered nurse practitioner \[ARNP\]) * AIM 1, COMMUNITY ORGANIZATION LEADERS: Age minimum of 18 * AIM 1, COMMUNITY ORGANIZATION LEADERS: Broadly defined as community leader (i.e. leadership in Seattle-area volunteer, philanthropic, community service groups) in discussions with with community-based participatory research (CBPR) partners * AIM 2: Current cigarette smoker (defined as actively smoking within the last 6 months, this is consistent with (c/w) standard and Seattle Cancer Care Alliance (SCCA) definition of current smoker) or former cigarette smoker * AIM 2: Aged 50-80 years * AIM 2: At least 20 pack-year smoking history * AIM 3: Identify as a member of the LGBTQ community * AIM 3: Eligible for no-cost sharing LCS based on United States Preventive Services Task Force (USPSTF) criteria * As of Jan 2022: aged 50-80 years, at least 20 pack-year smoking history, and currently smoke tobacco cigarettes \[as this intervention is based around current cigarette smokers (as defined above)\], former cigarette smokers not included in this Aim

Exclusion criteria

* AIM 1: Non-English speaking participants * AIM 2: Those found to be ineligible for LCS on coordinator review; or who are non-English speaking or have cognitive dysfunction that would prevent participation in SDM * AIM 3: Those found to be ineligible for LCS on coordinator review; or who are non-English speaking or have cognitive dysfunction that would prevent participation in SDM

Design outcomes

Primary

MeasureTime frameDescription
Number of lesbian, gay, bisexual, transgender (trans) and queer (LGBTQ) community stakeholders who participate in the Aim 1 interviews/focus groups (Aim 1)Up to 3 months
Number of LBGTQ community members who participate in the Aim 2 focus groups (Aim 2)Up to 9 months
Acceptability of patient navigation and smoking cessation interventions (Aim 3)Up to 12 monthsThe Acceptability of Intervention Measure (AIM) will be summarized and presented as range of scores from 1 (low acceptability) to 5 (high acceptability), with at least 75% of participants giving the interventions at least a 4, the threshold for acceptability.
Patient satisfaction with navigator throughout navigation and smoking cessation interventions (Aim 3)Up to 12 monthsThe Patient Satisfaction with Navigator (PSN-1) will also be summarized and presented as range of scores from 1 (high satisfaction) to 5 (low satisfaction), with at least 75% of participants giving the navigator interactions at maximum a 2, the threshold for satisfaction.
Effectiveness of navigation visit(s): knowledge (Aim 3)Up to 12 monthsPre- and post-intervention Lung cancer screening Knowledge Survey (LKS) responses will be compared via Cochran-Mantel-Haenszel tests for all categorical data.
Effectiveness of navigation visit(s): smoking cessation (Aim 3)Up to 12 monthsInitiation of pharmacotherapy and/or behavioral treatment, floating cigarette abstinence (\>7 days abstinence among those currently smoking at intervention start date, as defined in post-intervention survey) \[Aim 3\]

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026